A global IBM study reveals 60% of employees worry AI is diminishing their skills, especially critical thinking. While CHROs emphasize the need for judgment in AI oversight, employees rank it lower, highlighting a skills perception gap. Nearly half of organizations exclude HR leaders from AI strategy, risking accountability and workforce confidence issues. The study stresses redesigning work with human-AI collaboration to boost quality and reduce risks, urging HR to lead AI-driven workplace transformation despite current adoption challenges.
The IBM CHRO study on AI and workforce priorities is presented here alongside Pluang's Technology sector market snapshot as of Sep 21, 2026 09:11 WIB. Of 150 Technology stocks priced on Pluang, 80 rose and 69 fell today. ARM led gains with a 16.15% increase at USD 283.39 and a typical hold time of 27 days, contrasting with Intel's 11.61% rise to USD 112.78 and a longer hold time of 116 days, while AXT Inc gained 11.20% to USD 71.50 with a 16-day hold time.
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
